Vascular Imaging With Ferumoxytol as a Contrast Agent.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26102308.
- Also identified by DOI 10.2214/AJR.15.14534 and PMC identifier 5130335.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ferumoxytol is increasingly reported as an alternative to gadolinium-based contrast agents for MR angiography (MRA), particularly for patients with renal failure. This article summarizes more than 3 years of clinical experience with ferumoxytol-enhanced MRA for a range of indications and anatomic regions. Ferumoxytol-enhanced MRA has many advantages including that it is safe for patients with renal failure and provides a lengthy plateau of vascular signal as a blood pool agent that allows longer navigated MRA sequences.
Medical subject headings
- Contrast Media
- Ferrosoferric Oxide
- Magnetic Resonance Angiography
- Vascular Diseases